Par Drugs Q3 FY26 net profit jumps 8x to Rs 479.72 lakh, revenue up 37% YoY

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

PAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.4%Reaction day

₹96.72

prior close

₹100.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.5%+5.9% vs market

Pharmaceuticals peers, median of 159sector-0.0%+5.4% vs sector

On the reaction day the stock moved 5.9 pts more than Nifty Microcap 250 and 5.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+4.0

10m

+3.5

15m

+2.4

30m

+3.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.4-0.5+5.9-0.0+5.4

Next day

+2.4-1.0+3.4-0.2+2.5

-0.1-2.5+2.3-1.9+1.7

+2.4-3.2+5.5-2.4+4.8

+1.3-2.2+3.5-2.2+3.5

+5.5-1.9+7.4-1.9+7.4

+1.8-3.5+5.3-2.9+4.8

15d

-6.9-8.8+1.9-6.5-0.4

-6.9-9.3+2.3-6.6-0.3

-5.9-4.5-1.4-3.4-2.5

-3.2+5.4-8.6+3.6-6.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Par Drugs and Chemicals posted strong Q3 FY26 results. Revenue from operations rose 37% YoY to Rs 2,933.95 lakh, while net profit surged to Rs 479.72 lakh from Rs 57.80 lakh a year ago. For the nine months ended December 2025, revenue grew to Rs 8,404.48 lakh and PAT rose to Rs 1,225.49 lakh from Rs 1,170.69 lakh. Total expenses remained under control at Rs 2,422.30 lakh. EPS for the quarter stood at Rs 3.90.

Likely market impact

Sharp profit jump and revenue growth signal improved operating performance; positive for shareholder sentiment.